14937-32-7 Usage
Description
1,2,3,4,6-PENTA-O-GALLOYL-BETA-D-GLUCOPYRANOSE is a galloyl-beta-D-glucose compound characterized by the presence of five galloyl groups in the 1-, 2-, 3-, 4-, and 6-positions. It is a yellow powder with unique chemical properties that make it suitable for various applications.
Uses
1. Used in Pharmaceutical Applications:
1,2,3,4,6-PENTA-O-GALLOYL-BETA-D-GLUCOPYRANOSE is used as a pharmaceutical agent for its in vitro growth-inhibiting effect on human hepatocellular carcinoma cell line, SK-HEP-1 cells. This property makes it a potential candidate for the development of novel cancer treatments.
2. Used in Drug Delivery Systems:
In the field of drug delivery, 1,2,3,4,6-PENTA-O-GALLOYL-BETA-D-GLUCOPYRANOSE can be utilized as a component in the development of innovative drug delivery systems. Its unique chemical properties may contribute to enhancing the delivery, bioavailability, and therapeutic outcomes of various pharmaceutical compounds.
3. Used in Research and Development:
1,2,3,4,6-PENTA-O-GALLOYL-BETA-D-GLUCOPYRANOSE is also used as a research compound for studying its potential applications in various industries, including pharmaceuticals, cosmetics, and materials science. Its unique structure and properties make it an interesting subject for further investigation and development.
4. Used in Cosmetics Industry:
In the cosmetics industry, 1,2,3,4,6-PENTA-O-GALLOYL-BETA-D-GLUCOPYRANOSE may be used as an active ingredient in skincare and beauty products due to its potential biological activities and beneficial properties.
5. Used in Materials Science:
1,2,3,4,6-PENTA-O-GALLOYL-BETA-D-GLUCOPYRANOSE could be employed in materials science for the development of novel materials with specific properties, such as enhanced stability or biocompatibility, based on its unique chemical structure and characteristics.
Biochem/physiol Actions
Penta-O-galloyl-β-D-glucose hydrate (PCG) is a polyphenolic gallotannin compound produced by plants. It has an ability to inhibit matrix metalloproteinase (MMP) related metastatic activity. Thus, PCG can be used for treating metastatic activity in squamous cell carcinoma. In addition, it also acts as a potential drug for stabilizing small abdominal aneurysms.
Check Digit Verification of cas no
The CAS Registry Mumber 14937-32-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,4,9,3 and 7 respectively; the second part has 2 digits, 3 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 14937-32:
(7*1)+(6*4)+(5*9)+(4*3)+(3*7)+(2*3)+(1*2)=117
117 % 10 = 7
So 14937-32-7 is a valid CAS Registry Number.
InChI:InChI=1/C41H32O26/c42-17-1-12(2-18(43)28(17)52)36(57)62-11-27-33(64-37(58)13-3-19(44)29(53)20(45)4-13)34(65-38(59)14-5-21(46)30(54)22(47)6-14)35(66-39(60)15-7-23(48)31(55)24(49)8-15)41(63-27)67-40(61)16-9-25(50)32(56)26(51)10-16/h1-10,27,33-35,41-56H,11H2/t27-,33-,34+,35-,41+/m1/s1
14937-32-7Relevant articles and documents
Tellimagrandin I, HCV invasion inhibitor from Rosae Rugosae Flos
Tamura, Satoru,Yang, Gang-Ming,Yasueda, Natsuko,Matsuura, Yoshiharu,Komoda, Yasumasa,Murakami, Nobutoshi
, p. 1598 - 1600 (2010)
By use of the model virus, expressing the HCV envelope proteins E1 and E2, bioassay guided separation of the MeOH extract from Rosa rugosa Thunb. disclosed tellimagrandin I (1) together with eugeniin (2) and casuarictin (3) as the potent HCV invasion inhibitors. Furthermore, structure-activity relationship analysis of some relative tannins including the synthesized analogs elucidated the partial structures crucial for potent activity of 1.
1,2,3,4,6-Pentakis[-O-(3,4,5-trihydroxybenzoyl)]-α,β-D-glucopyranose (PGG) analogs: Design, synthesis, anti-tumor and anti-oxidant activities
Shaikh, Qurat-Ul-Ain,Yang, Meiting,Memon, Khadim Hussain,Lateef, Mehreen,Na, Du,Wan, Shengbiao,Eric, Deslandes,Zhang, Lijuan,Jiang, Tao
, p. 72 - 81 (2016/05/24)
1,2,3,4,6-Pentakis[-O-(3,4,5-trihydroxybenzoyl)]-α,β-D-glucopyranose (PGG) 12 has been reported for its antioxidant activities, where the free OH groups in PGG seem to be critical for activities. To explore PGG-based compounds as chemotherapeutic agents and to analyze the contribution of specific OH groups in PGG for anti-cancer activities, we designed and synthesized a series of 27 benzoic and cinnamic acid analogs of PGG. These analogs were tested for cytotoxicities against two human lung (A549 and H1299) and two human colon (HCT116 and HT29) cancer cell lines. Compound 12 (PGG) had highest cytotoxicities against HCT116 and A549 cells with IC50 of 1.61 μM and 3.02 μM, respectively. In contrast, the compound 16 (1,2,3,4,6-pentakis[-O-(4-hydroxy-3-methoxybenzoyl)]-α,β-D-glucopyranose, PVG) was most effective at killing HT29 and H1299 cells with IC50 of 1.76 μM and 3.65 μM, respectively, indicating the mutual contribution of m-methoxy and p-hydroxy groups to the observed cytotoxicities. Moreover, cinnamic acid analogs were less active than the benzoic acid analogs evidenced by higher IC50 values. Furthermore, in cinnamic acid analogs the hydrogenation of double bond to saturated 2-C side chain enhance the cytotoxicities in all four cell lines. Compounds also possess good anti-oxidant and reducing activities. Compound 12 and 26 show the highest antioxidant and reducing activities.
Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism
-
Page/Page column 61, (2015/09/22)
The invention relates to plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or condition associated with elevated PAI-1. The invention includes, but is not limited to, the use of such compounds to modulate lipid metabolism and treat conditions associated with elevated PAI-1, cholesterol, or lipid levels.
